Nuedexta Shortage: What Providers and Prescribers Need to Know in 2026

Nuedexta (dextromethorphan 20 mg / quinidine sulfate 10 mg) remains the only FDA-approved pharmacotherapy for pseudobulbar affect (PBA). While it is not on the FDA's official drug shortage list as of 2026, providers are fielding calls from patients who cannot access their prescriptions. This guide is designed to help clinicians understand the landscape, navigate prior authorization, identify alternatives, and connect patients with support programs.

The Current Nuedexta Access Landscape for Providers

As of 2026, Nuedexta is not on the FDA Drug Shortages list, and Avanir Pharmaceuticals (now under Otsuka) continues to manufacture and distribute the product. The access challenges your patients face stem primarily from:

Inconsistent stocking at retail pharmacies. Nuedexta's relatively small patient population means most retail pharmacies don't maintain standing inventory. Specialty pharmacies are the more reliable access point.

Prior authorization requirements. Virtually all commercial plans and Medicare Part D formularies require PA for Nuedexta. Denial rates on first submission are not trivial, particularly when documentation of the underlying neurological condition and PBA symptomatology is incomplete.

Step therapy requirements. Some plans require documentation of prior antidepressant (SSRI or TCA) failure before approving Nuedexta, even though Nuedexta is the only FDA-approved agent for PBA.

Medicare formulary placement. Nuedexta often appears on Tier 3 or higher in Medicare Part D plans, resulting in significant out-of-pocket costs for elderly patients who cannot use the manufacturer's co-pay card.

Prior Authorization Documentation: What Payers Want to See

A strong prior authorization submission for Nuedexta should include:

Confirmed diagnosis of pseudobulbar affect (ICD-10 code: F48.2)

Documentation of the underlying neurological condition (ALS, MS, stroke, TBI, Parkinson's, Alzheimer's) with appropriate ICD-10 coding

CNS-Lability Scale (CNS-LS) score or clinical description of PBA episode frequency and severity

Statement that PBA is distinct from the patient's primary mood symptoms

Documentation of step therapy compliance if required by the plan (prior trial and failure/intolerance of SSRI or TCA)

Avanir provides downloadable Sample Letters of Medical Necessity (Basic and Comprehensive templates) at nuedextahcp.com/access-and-affordability. Dedicated Field Reimbursement Managers (FRMs) are available to support providers through the PA process and can be reached at 1-833-468-7852, Monday–Friday, 8 AM–8 PM Eastern.

Key Drug Interactions Providers Must Screen For

PBA patients typically have complex neurological comorbidities and polypharmacy. Before initiating Nuedexta, screen for:

MAOIs (contraindicated): Risk of serotonin syndrome. Allow at least 14 days after stopping Nuedexta before starting an MAOI, and 14 days after stopping an MAOI before starting Nuedexta.

SSRIs/TCAs: Quinidine inhibits CYP2D6; co-administration increases SSRI and TCA levels. Reduce paroxetine dose (max 35 mg/day) and desipramine dose (max 40 mg/day) if co-prescribing.

Digoxin: Quinidine inhibits P-glycoprotein; may double digoxin plasma levels. Monitor digoxin concentrations closely.

QT-prolonging agents: Avoid concomitant use with drugs that both prolong QT and are metabolized by CYP2D6 (thioridazine, pimozide). Obtain ECG at baseline and 3–4 hours after first dose in at-risk patients.

Quinidine/quinine/mefloquine (contraindicated): Do not co-administer.

Cardiac Monitoring Requirements

Nuedexta is contraindicated in patients with prolonged QT interval, congenital long QT syndrome, heart failure, complete AV block without pacemaker, or history of torsades de pointes. For patients at cardiovascular risk, perform an ECG at baseline and 3–4 hours after the first dose to assess QTc prolongation.

Off-Label Alternatives When Nuedexta Is Not Accessible

When Nuedexta is inaccessible due to coverage denial, formulary barriers, or contraindications, off-label antidepressants remain the next best evidence-based options:

SSRIs: Fluoxetine 20 mg/day, citalopram 10–30 mg/day, and sertraline 50 mg/day have clinical evidence in small PBA studies. Generally first-line among alternatives due to favorable tolerability.

TCAs: Amitriptyline and nortriptyline at sub-therapeutic antidepressant doses. Anticholinergic side effects limit use in ALS (sialorrhea benefit), Parkinson's, and elderly patients. Monitor for cardiac effects.

Connecting Your Patients to Support Resources

For patients struggling to locate Nuedexta at their local pharmacy, medfinder for providers offers a service where medfinder calls pharmacies on the patient's behalf to locate available stock. This can dramatically reduce the time patients spend searching and help maintain treatment continuity.

Manufacturer support programs include:

Co-pay savings card: Commercially insured patients pay as little as $0 for a 90-day supply or $20 for a 30-day supply (max savings $1,335/use; $2,670/year). Activate at nuedexta.com/activate.

Otsuka Patient Assistance Foundation: Free medication for eligible uninsured/underinsured patients. Call 1-855-468-3339.

PA appeal support: FRMs and CoverMyMeds integration for electronic PA submission. 1-833-468-7852.

Summary for Prescribers

Nuedexta is available but requires proactive management of the access pathway — specialty pharmacy referral, complete PA documentation, and patient enrollment in savings programs. For a step-by-step provider workflow, see our guide on how to help your patients find Nuedexta in stock.